CoChat

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Huynh, Hung, Hao, Huai-Xiang, Chan, Stephen L., Chen, David, Ong, Richard, Soo, Khee Chee, Pochanard, Panisa, Yang, David, Ruddy, David, Liu, Manway, Derti, Adnan, Balak, Marissa N., Palmer, Michael R., Wang, Yan, Lee, Benjamin H., Sellami, Dalila, Zhu, Andrew X., Schlegel, Robert, Huang, Alan · 2015 · Molecular Cancer Therapeutics
Cited by 79

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and hyperactivation of mTOR signaling plays a pivotal role in HCC tumorigenesis. Tuberous sclerosis complex (TSC), a heterodimer of TSC1 and TSC2, functions as a negative regulator of mTOR signaling. In the current study, we discovered that TSC2 loss-of-function is common in HCC. TSC2 loss was found in 4 of 8 HCC cell lines and 8 of 28 (28.6%) patient-derived HCC xenografts. TSC2 mutations and deletions are likely to be the underlying cause of TSC2 loss in HCC cell lines, xenografts, and primary tumors for most cases. We further demonstrated that TSC2-null HCC cell lines and xenografts had elevated mTOR signaling and, more importantly, were significantly more sensitive to RAD001/everolimus, an mTORC1 inhibitor. These preclinical findings led to the analysis of TSC2 status in HCC samples collected in the EVOLVE-1 clinical trial of everolimus using an optimized immunohistochemistry assay and identified 15 of 139 (10.8%) samples with low to undetectable levels of TSC2. Although the sample size is too small for formal statistical analysis, TSC2-null/low tumor patients who received everolimus tended to have longer overall survival than those who received placebo. Finally, we performed an epidemiology survey of more than 239 Asian HCC tumors and found the frequency of TSC2 loss to be approximately 20% in Asian HBV+ HCC. Taken together, our data strongly argue that TSC2 loss is a predictive biomarker for the response to everolimus in HCC patients. Mol Cancer Ther; 14(5); 1224–35. ©2015 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-14-0768

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 79

Metadata

Authors
Huynh, H., Hao, H.-X., Chan, S. L., Chen, D., Ong, R., Soo, K. C., Pochanard, P., Yang, D., Ruddy, D., Liu, M., Derti, A., Balak, M. N., Palmer, M. R., Wang, Y., Lee, B. H., Sellami, D., Zhu, A. X., Schlegel, R., & Huang, A.
Venue
Molecular Cancer Therapeutics
Published
2015-05-01
Volume
14
Issue
5
Pages
1224-1235
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2171402611
Cited by
79
References
8
FWCI
5.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. https://app.cochat.ai/papers/10.1158/1535-7163.mct-14-0768
The paper
Huynh, H., Hao, H.-X., Chan, S. L., Chen, D., Ong, R., Soo, K. C., Pochanard, P., Yang, D., Ruddy, D., Liu, M., Derti, A., Balak, M. N., Palmer, M. R., Wang, Y., Lee, B. H., Sellami, D., Zhu, A. X., Schlegel, R., & Huang, A. (2015). Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-14-0768

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.